Skip to main content

Zembrace SymTouch News

No Increase Seen in Neurodevelopmental Disorders With Prenatal Triptan Use

WEDNESDAY, May 21, 2025 – Children prenatally exposed to different triptan intensities and duration, alone or in combination with other preventive medications for migraine, do not have increased...

Combination Therapy Recommended For Migraines

THURSDAY, March 20, 2025 – Doctors should prescribe triptans for migraine patients who aren’t receiving relief from over-the-counter (OTC) pain relievers, according to a new clinical guideline from t...

FDA Approves Tosymra (sumatriptan) Nasal Spray for Acute Treatment of Migraine

January 27, 2019 – Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC today announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration ...

Dr. Reddy’s Laboratories Ltd. Receives FDA Approval for Zembrace SymTouch (sumatriptan succinate) Injection for the Acute Treatment of Migraines

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the U.S. Food and Drug Administration (FDA) has approved...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Migraine

Zembrace SymTouch patient information at Drugs.com